Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Recruiting 3Not yet recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 3Dermatologic 1

Conditions

Triple Negative Breast Neoplasms 3Breast Neoplasms 2Melanoma 1

Interventions

Specimen Handling 648pembrolizumab 606Magnetic Resonance Spectroscopy 559Carboplatin 446Cyclophosphamide 394Cisplatin 394Biopsy 376Nivolumab 325Paclitaxel 324Gemcitabine 317Radiotherapy 295Bevacizumab 245Dexamethasone 224fludarabine 214Docetaxel 202durvalumab 194Oxaliplatin 191venetoclax 187atezolizumab 179Fluorouracil 179Rituximab 174Capecitabine 170Pemetrexed 169Radiation 164Doxorubicin 164Radiosurgery 161Ipilimumab 148Lenalidomide 143Leucovorin 139Etoposide 139

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
famitinib × 90 days × Clear all
NCT05582499 2026-05-28

FASCINATE-N

Fudan University

Phase 2 Recruiting
716 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05749588 2026-04-16

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Fudan University

Phase 2 Recruiting
120 enrolled
Breast

Triple Negative Breast Neoplasms

NCT06649331 2026-04-08

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Fudan University

Phase 2 Recruiting
160 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07517653 2026-04-08

Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma

Shanghai Zhongshan Hospital

Phase 2 Not yet recruiting
70 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡